Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab.

Abstract

Alemtuzumab has recently been approved for the treatment of relapsing-remitting multiple sclerosis (MS) in Europe and North America. With its broad mechanism of action on the cellular immune system and high efficacy within the approved indication, alemtuzumab may also be considered as a rescue therapy in other autoimmune conditions, like neuromyelitis optica spectrum diseases (NMOSD). However, data on its potency and safety in NMOSD are largely lacking.